CP94253 hydrochloride

CP94253 hydrochloride 是一种具有口服活性且可穿透血脑屏障的 5-HT1B 受体选择性激动剂(Ki 值为 2 nM),可诱导类抗抑郁效应、觉醒增强、睡眠抑制、睡眠潜伏期延长、运动亢进及攻击行为抑制,并可用于抑郁症及攻击行为亢进的相关研究。
产品编号: MS-X97698 纯度: 98.00% CAS No.: 845861-39-4 分子式: C15H20ClN3O 分子量: 293.79
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

CP94253 hydrochloride 是一种具有口服活性且可穿透血脑屏障的 5-HT1B 受体选择性激动剂(Ki 值为 2 nM),可诱导类抗抑郁效应、觉醒增强、睡眠抑制、睡眠潜伏期延长、运动亢进及攻击行为抑制,并可用于抑郁症及攻击行为亢进的相关研究。

生物实验数据

生物活性 CP94253 hydrochloride is an orally active, blood-brain barrier-penetrant, selective 5-HT1B receptor agonist with a Ki value of 2 nM that induces antidepressant-like effects, enhanced arousal, sleep suppression, prolonged sleep latency, hyperactivity, and inhibition of aggressive behavior, and can be used in research related to depression and hyperaggression.
IC50 & Target

5-HT1B Receptor

2 nM (Ki)

5-HT1A Receptor

89 nM (Ki)

5-HT1D Receptor

49 nM (Ki)

5-HT2A Receptor

1600 nM (Ki)

5-HT2C Receptor

860 nM (Ki)

体外研究
(In Vitro)

CP94253 hydrochloride 可强效且选择性地结合 5-HT1B 受体 (Ki = 2 nM),对其他血清素受体亚型的亲和力极低,且与多种脱靶受体无显著结合作用。
CP94253 (1.0-2.0 nM) hydrochloride 可作为竞争性抑制剂,抑制 [125I]iodocyanopindolol 与大鼠大脑皮层细胞膜 5-HT1B 受体的结合。
CP94253 (50-100 nM) hydrochloride 可竞争性抑制 [3H]5-HT 与牛尾状核膜 5-HT1D 受体的结合。

体内研究
(In Vivo)

CP94253 (1-10 mg/kg;腹腔注射;单次给药) hydrochloride 可剂量依赖性地减少雌性 Wistar 大鼠的摄食量,其在首次摄食 1 小时内的腹腔注射 ED50 为 3.48 mg/kg;该药物的摄食抑制作用不依赖 5-HT2C 受体,且预先给予低剂量无活性的 5-HT2C 激动剂 ORG 37684 (MS-M04334) 可增强其摄食抑制效应。
CP94253 (5 mg/kg;腹腔注射;单次给药) hydrochloride 在小鼠中发挥强效类抗抑郁作用,可将强迫游泳实验中的不动时间缩短 43%;其作用机制为激活 5-HT1B 受体 (可能为突触后受体或异源受体),且多巴胺和去甲肾上腺素系统对该作用有介导作用。
CP94253 (0.5-10.0 mg/kg;皮下注射) hydrochloride 激活 5-HT1B 受体,可在雄性 Wistar 大鼠中呈剂量依赖性增加觉醒时长,在 5.0-10.0 mg/kg 剂量下减少慢波睡眠 (SWS),并在所有测试剂量下抑制快速眼动睡眠 (REMS)。
CP94253 (5.0-10.0 mg/kg;皮下注射) hydrochloride 诱导的雄性 Wistar 大鼠觉醒时间增加和慢波睡眠 (SWS) 减少可被 2.0 mg/kg (±) Pindolol (MS-M23863) 预处理逆转。
CP94253 (3.2-32 mg/kg;口服;每日一次;连续 9 天) hydrochloride 经口服给予健康大鼠后,在 32 mg/kg 剂量下会引发短暂厌食、持续的体重增长减缓以及持续性活动过度,而 3.2 mg/kg 和 10 mg/kg 剂量对这些终点指标无显著影响。
CP94253 (3-17 mg/kg;腹腔注射;单次给药) hydrochloride 可剂量依赖性地降低雄性 CFW 小鼠的种属特异性攻击行为,其中其减少攻击撕咬的 ED50 为 7.2 mg/kg;GR 127935 (MS-I73621) 的拮抗作用以及 WAY 100,635 (MS-L56483) 无作用的结果表明,该效应特异性作用于 5-HT1B 受体,且不会同时引发运动性镇静。
CP94253 (3-10 mg/kg;腹腔注射;单次给药) hydrochloride 可降低雄性 CFW 小鼠中酒精诱导增强的攻击性,其 ED50 (3.8 mg/kg) 低于针对非增强攻击性的 ED50;该药物具有剂量依赖性效应,仅在测试的最高剂量下会降低自主活动行为。
CP94253 (1-10 mg/kg;腹腔注射;单次给药) hydrochloride 可降低雄性 CFW 小鼠经激惹诱导的攻击性,其 ED50 (2.7 mg/kg) 低于非激惹诱导的攻击性模型;仅在较高剂量下,该药物才会对自发活动行为产生剂量依赖性影响。
CP94253 (5-40 µmol/kg;腹腔注射;喂食前 30 分钟单次给药) hydrochloride 可在轻度禁食的进食颗粒饲料大鼠中产生强效摄食抑制作用,其 ID50 为 12.5 µmol/kg;该作用通过缩短进食时长、降低进食频率实现,且不会改变大鼠的静息行为。
CP94253 (5-28 µmol/kg;腹腔注射;蔗糖摄入前 30 分钟单次给药) hydrochloride 可在轻度禁食且摄入 10% 蔗糖的大鼠中产生摄食抑制效应,其 ID50 为 22.8 µmol/kg;该效应通过缩短进食时长、降低进食频率及舔舐爆发/集群频率实现,且不会损害口腔运动效率。

Animal Model: Wistar (female, ~200 g body weight)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.p.; single dose
Result: Induced a dose-dependent reduction of food intake, with an ED50 value of 3.48 mg/kg for the first hour of food access.
Showed hypophagic effect unaffected by pretreatment with 5-HT2C receptor antagonists metergoline or SB 242,084.
Had hypophagic effect potentiated by pretreatment with a low, inactive dose of ORG 37684, lowering its ED50 to 2.44 mg/kg for the 0-1 h interval, 1.19 mg/kg for the 0-2 h interval, and 1.93 mg/kg for the 0-6 h interval.
Animal Model: Albino Swiss (male, 24-26 g)
Dosage: 5 mg/kg
Administration: i.p.; single dose
Result: Shortened the immobility time of mice by 43%.
Did not alter spontaneous locomotor activity of mice.
Animal Model: Wistar (male, 350-380 g, implanted with chronic sleep recording electrodes, habituated to recording chambers and injection procedures)
Dosage: 0.5 mg/kg; 1.0 mg/kg; 5.0 mg/kg; 10.0 mg/kg
Administration: s.c.
Result: Decreased REM sleep to 8.8 minutes and number of REM periods to 3.5 during 0-3 hour period at 0.5 mg/kg; no significant changes to waking, slow wave sleep, or light sleep observed at 0.5 mg/kg.
Decreased REM sleep to 4.3 minutes and number of REM periods to 2.0, and increased REM sleep latency to 90.8 minutes during 0-3 hour period at 1.0 mg/kg; decreased REM sleep to 11.0 minutes and number of REM periods to 4.1 during 4-6 hour period at 1.0 mg/kg.
Increased waking to 86.0 minutes, decreased slow wave sleep to 71.9 minutes and REM sleep to 1.4 minutes, increased REM sleep latency to 164.6 minutes, and decreased number of REM periods to 0.7 during 0-3 hour period at 5.0 mg/kg; increased waking to 58.4 minutes, decreased slow wave sleep to 92.6 minutes and REM sleep to 4.7 minutes, and decreased number of REM periods to 2.3 during 4-6 hour period at 5.0 mg/kg.
Increased waking to 96.9 minutes and light sleep to 34.5 minutes, decreased slow wave sleep to 48.3 minutes and REM sleep to 0.3 minutes, increased slow wave sleep latency to 23.4 minutes and REM sleep latency to 239.2 minutes, and decreased number of REM periods to 0.2 during 0-3 hour period at 10.0 mg/kg; increased waking to 79.9 minutes and light sleep to 36.8 minutes, decreased slow wave sleep to 59.1 minutes and REM sleep to 4.2 minutes, and decreased number of REM periods to 2.0 during 4-6 hour period at 10.0 mg/kg.
Animal Model: Wistar (male, 350-380 g, implanted with chronic sleep recording electrodes, pretreated with (±) pindolol)
Dosage: 5.0 mg/kg plus 2.0 mg/kg (±) Pindolol; 10.0 mg/kg plus 2.0 mg/kg (±) Pindolol
Administration: s.c.
Result: Decreased REM sleep to 2.9 minutes and number of REM periods to 1.6, and increased REM sleep latency to 125.0 minutes during 0-3 hour period at 5.0 mg/kg with (±) Pindolol pretreatment.
Decreased REM sleep to 6.0 minutes and number of REM periods to 2.9 during 4-6 hour period at 5.0 mg/kg with (±) Pindolol pretreatment.
No significant changes to waking or slow wave sleep observed at 5.0 mg/kg with (±) Pindolol pretreatment.
Decreased REM sleep to 2.7 minutes and number of REM periods to 1.6, and increased REM sleep latency to 135.6 minutes during 0-3 hour period at 10.0 mg/kg with (±) Pindolol pretreatment.
Decreased REM sleep to 3.4 minutes and number of REM periods to 3.1 during 4-6 hour period at 10.0 mg/kg with (±) Pindolol pretreatment.
No significant changes to waking or slow wave sleep observed at 10.0 mg/kg with (±) Pindolol pretreatment.
Animal Model: Charles River Sprague-Dawley CD (male, 170-190 g)
Dosage: 3.2 mg/kg; 10 mg/kg; 32 mg/kg
Administration: p.o.; daily; 9 days
Result: Reduced food intake significantly in the first 24 hours (to ~14 g/24 hr, compared to vehicle ~24 g/24 hr), with the anorectic effect diminishing over time and returning to vehicle levels by day 7.
Inhibited body weight gain after the first and second injections, with a persistent weight differential relative to vehicle-treated rats maintained for the entire study (day 9 body weight ~290 g, compared to vehicle ~320 g).
Induced a ~2-fold increase in horizontal locomotion relative to vehicle starting on day 1, which persisted throughout the 9-day study with slight evidence of tolerance.
Showed no significant effect on food intake or body weight gain relative to vehicle at 3.2 mg/kg and 10 mg/kg.
Exerted little or no effect on horizontal locomotion at 3.2 mg/kg and 10 mg/kg.
Animal Model: CFW (male, adult, 20-25 g, arrived at 5 weeks old)
Dosage: 3.0 mg/kg; 5.6 mg/kg; 10.0 mg/kg; 17.0 mg/kg; 10 mg/kg plus GR 127935; 17 mg/kg plus GR 127935; 30 mg/kg plus GR 127935
Administration: i.p.; single dose
Result: Reduced attack bite and tail rattle frequencies significantly at all tested doses (3-17 mg/kg).
Reduced sideways threats significantly at 10.0 and 17.0 mg/kg.
Achieved an ED50 of 7.2 mg/kg for attack bite reduction.
Shifted the ED50 for attack bite reduction to 14.5 mg/kg when pretreated with GR 127935.
Shifted the ED50 for sideways threat reduction to 15.6 mg/kg when pretreated with GR 127935.
Did not alter anti-aggressive effects when pretreated with WAY 100,635.
Did not reduce locomotor behaviors (walking, rearing) at any tested dose.
Decreased grooming duration at all doses.
Animal Model: CFW (male, adult, 20-25 g, arrived at 5 weeks old)
Dosage: 3.0 mg/kg; 5.6 mg/kg; 10.0 mg/kg
Administration: i.p.; single dose
Result: Reduced attack bite and sideways threat frequencies significantly at all tested doses (3-10 mg/kg).
Reduced tail rattle frequency at 10.0 mg/kg.
Achieved an ED50 of 3.8 mg/kg for attack bite reduction in alcohol-heightened aggression mice, which was significantly lower than the ED50 of 7.1 mg/kg in alcohol-non-heightened aggression mice.
Reduced locomotor behaviors (walking, rearing) only at the 10.0 mg/kg dose.
Did not significantly affect grooming duration.
Animal Model: CFW (male, adult, 20-25 g, arrived at 5 weeks old)
Dosage: 1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg
Administration: i.p.; single dose
Result: Reduced attack bite and sideways threat frequencies significantly at 3.0 and 10.0 mg/kg.
Achieved an ED50 of 2.7 mg/kg for attack bite reduction in instigation-heightened aggression mice, which was significantly lower than the ED50 of 8.3 mg/kg for non-instigated aggression.
Reduced walking duration at 3.0 and 10.0 mg/kg.
Reduced rearing and grooming durations only at 10.0 mg/kg.
Animal Model: Sprague-Dawley (male, mildly food-deprived)
Dosage: 5 µmol/kg; 10 µmol/kg; 14 µmol/kg; 20 µmol/kg; 40 µmol/kg
Administration: i.p.; single injection 30 minutes prior to feeding
Result: Produced a dose-related decrease in 30-minute pellet intake, with significant reductions at 10, 14, 20, and 40 µmol/kg.
Reduced water intake in a non-systematic, non-dose-related manner across all doses.
Reduced the frequency of feeding observations at all doses.
Shortened meal duration in a dose-related manner.
Increased standing at the 20 µmol/kg dose.
Left resting frequency unchanged.
Induced an abnormal prone posture at the 40 µmol/kg dose.
Achieved an ID50 of 12.5 µmol/kg for pellet intake reduction.
Animal Model: Sprague-Dawley (male, mildly food-deprived)
Dosage: 5 µmol/kg; 10 µmol/kg; 14 µmol/kg; 20 µmol/kg; 40 µmol/kg
Administration: i.p.; single injection 30 minutes prior to sucrose access
Result: Produced a dose-related decrease in 30-minute sucrose intake, with significant reductions at 20 and 28 µmol/kg.
Reduced the frequency of feeding observations at 20 and 28 µmol/kg.
Shortened meal duration in a dose-related manner.
Increased standing at the 28 µmol/kg dose.
Left resting frequency unchanged.
Reduced the total number of licks at 20 and 28 µmol/kg, with lick efficiency unchanged.
Decreased the frequency of licking bursts and clusters without altering their size.
Achieved an ID50 of 22.8 µmol/kg for sucrose intake reduction.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 293.79
分子式 C15H20ClN3O
CAS No. 845861-39-4

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (13.62 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (34.04 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (425.47 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.4038 mL17.0190 mL34.0379 mL85.0948 mL
5 mM0.6808 mL3.4038 mL6.8076 mL17.0190 mL
10 mM0.3404 mL1.7019 mL3.4038 mL8.5095 mL
15 mM0.2269 mL1.1346 mL2.2692 mL5.6730 mL
20 mM0.1702 mL0.8509 mL1.7019 mL4.2547 mL
25 mM0.1362 mL0.6808 mL1.3615 mL3.4038 mL
30 mM0.1135 mL0.5673 mL1.1346 mL2.8365 mL
40 mM0.0851 mL0.4255 mL0.8509 mL2.1274 mL
50 mM0.0681 mL0.3404 mL0.6808 mL1.7019 mL
60 mM0.0567 mL0.2836 mL0.5673 mL1.4182 mL
80 mM0.0425 mL0.2127 mL0.4255 mL1.0637 mL
100 mM0.0340 mL0.1702 mL0.3404 mL0.8509 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础